Navigation Links
Medarex Highlights Oncology Pipeline at Needham Cancer Therapeutics Conference in New York City
Date:3/26/2009

PRINCETON, N.J., March 26 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX) today announced that Dr. Geoffrey M. Nichol, Senior Vice President of Product Development at Medarex presented highlights from key programs in Medarex's oncology portfolio at the Needham & Company Cancer Therapeutics: Today & Tomorrow Conference in New York. The archived edition of the presentation webcast is available in the Investor Relations section of the Medarex website at www.medarex.com.

Highlights from Medarex's oncology portfolio included the following:

  • Ipilimumab is a fully human anti-CTLA-4 antibody in development for melanoma, prostate cancer and other cancers. Guidance for the completion of the first-line Phase 3 chemotherapy combination trial in melanoma (study 024) remains unchanged and is expected in late 2009, with overall survival as the primary endpoint under the amended Special Protocol Assessment agreement with the U.S. Food and Drug Administration. Initiation of the second-line Phase 3 radiotherapy combination trial in prostate cancer remains on track for mid-2009. Additional data, including survival and biomarker analyses from the melanoma Phase 2 program and data from the Phase 2 prostate program, will be presented at the upcoming annual meeting of the American Society of Clinical Oncology (ASCO) in May/June.
  • MDX-1105 and MDX-1106 are two fully human antibodies that target the PD-L1/PD-1 pathway for the treatment of cancer. MDX-1105 is in an ongoing multi-dose Phase 1 trial for advanced or recurrent renal cancer, melanoma, non-small cell lung cancer or epithelial cancer. MDX-1106 is in an ongoing multi-dose Phase 1b trial for prostate cancer, melanoma, non-small cell lung cancer and renal cancer. Complete MDX-1106 Phase 1 data will
    '/>"/>

SOURCE Medarex, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Medarex Announces 2008 Fourth Quarter and Year End Financial Results
2. Medarex to Announce 2008 Fourth Quarter and Year-End Financial Results on Wednesday, February 25, 2009
3. Medarex to Receive Milestone Payment from MedImmune for Allowance of an Investigational New Drug Application for MEDI-546
4. Medarex Reviews Recent Highlights and Outlook for 2009
5. Medarex to Receive Milestone Payment for Approval of STELARA(TM) (Ustekinumab) for the Treatment of Moderate to Severe Plaque Psoriasis
6. Medarex Hosts June 2nd Webcast of Ipilimumab Data Presented at ASCO
7. Medarex Announces 2008 First Quarter Financial Results
8. Medarex and Bristol-Myers Squibb Joint Statement on Submission Status of Ipilimumab
9. Medarex Announces 2007 Fourth Quarter and Year End Financial Results
10. Medarex to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
11. Medarex to Receive Milestone Payment for Submission of Regulatory Applications Requesting Approval of Ustekinumab (CNTO 1275) for Treatment of Psoriasis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... HealthDay Reporter MONDAY, Sept. ... twice as often as they,re actually needed for children ... More than 11 million antibiotic prescriptions written each ... to researchers from University of Washington and Seattle Children,s ... eradicate children,s viral illnesses, researchers said, but supports the ...
(Date:9/15/2014)... -- Births of multiple babies cost more and pose ... researchers report. The researchers suggest that limiting embryo ... ease some of that burden. Over the past ... births to older mothers and use of assisted reproductive ... South Wales, Australia. Their study, published online Sept. ...
(Date:9/15/2014)... PA (PRWEB) September 15, 2014 ... private insurance exchange technology, today announced that ... insurance organization in southeastern Pennsylvania, has selected the ... private health insurance exchange marketplace for employers with ... provided by Array Spectrum™, Independence will offer employer ...
(Date:9/15/2014)... New York (PRWEB) September 15, 2014 ... in U.S. courts, Bernstein Liebhard LLP notes that a ... be useful in curbing aggression in children with ADHD ... and parent training in behavioral management techniques. According to ... children with ADHD and aggression problems, half of whom ...
(Date:9/15/2014)... had a heart attack are at greater risk of death ... is missed, according to a new study. Researchers ... of their treatment early on, such as an electrocardiogram within ... steps in their care later on. The researchers added, however, ... all nine steps critical to their care are followed. , ...
Breaking Medicine News(10 mins):Health News:Kids Prescribed Antibiotics Twice as Often as Needed, Study Finds 2Health News:Kids Prescribed Antibiotics Twice as Often as Needed, Study Finds 3Health News:Study Ties Multiple Births to Higher Costs, Complications 2Health News:Study Ties Multiple Births to Higher Costs, Complications 3Health News:Independence Blue Cross Selects Array Spectrum™ Private Health Insurance Exchange Technology 2Health News:Independence Blue Cross Selects Array Spectrum™ Private Health Insurance Exchange Technology 3Health News:Risperdal News: Bernstein Liebhard LLP Notes New Study Regarding Risperdal and Children with ADHD 2Health News:Risperdal News: Bernstein Liebhard LLP Notes New Study Regarding Risperdal and Children with ADHD 3Health News:Risperdal News: Bernstein Liebhard LLP Notes New Study Regarding Risperdal and Children with ADHD 4Health News:Heart Attack Patients Face Greater Death Risk if Any Treatment Step Missed: Study 2
... can bring relief to people who snore and suffer from sleep ... The device is named as 'aveoTSD' and is the result of ... related to a range of problems from high blood pressure and ... by snoring partners. , ,The device is like using a ...
... Researchers from Slovenia had been able to unravel the ... the August issue of CHEST, the peer-reviewed journal of ... study of 40 patients, researchers used CT scan imaging ... structures responsible for snoring. ,Based on questionnaires ...
... Philadelphia, Aug 15. The best single predictor of happiness ... marital status only follow health as per a recent ... and graduate student Laura Tach from Harvard University measured ... 20-to-64-year-olds using analysis from the 1972-2002 General Social Survey. ...
... does not discriminate between rich and poor, if ... celebrities have succumbed to it and some have ... these famous// actresses and personalities who have suffered ... and Singer,Shirley Temple Black - Actress/singer/diplomat,Jill Eikenberry, Actress,Nancy ...
... differs in their ability to exercise for better physical ... that an enzyme involved in blood pressure regulation may ... findings, by researchers at Wake Forest University School of ... of the American Medical Association., ,The study is ...
... leading cause of blindness that affects millions of people ... Taking vitamin E supplements, as well as a higher ... , could slow cataract progression. , ,Although surgical ... researchers say they are investigating whether dietary changes can ...
Cached Medicine News:Health News:Rich are happier then Poor 2Health News:Gene Decides How Much Exercise In Needed For The Elderly People 2
(Date:9/15/2014)... -- The Society of Corporate Compliance and Ethics ... 4,500 compliance and ethics professionals from across industry, ... fines and settlements.  The SCALENDAR is designed to ... reference to demonstrate to employees the consequences of ... help compliance and ethics officers looking for a ...
(Date:9/15/2014)... , Sept. 15, 2014 Research and ... "Closed Drug Transfer Systems to 2020" report to ... deemed hazardous to humans has been receiving increasing amounts ... these substances become more clearly understood. For caregivers and ... forefront of attempts to mitigate exposure to cytotoxic drugs ...
(Date:9/15/2014)... Sept. 15, 2014 Sysmex America, a ... systems technology, announced today an amended distributorship agreement ... for Sysmex reagents, controls and instruments including the ... ™ , Sysmex XP-300™, XT-Series and XN-Series Automated ... effective immediately and continues until August 31, 2017.  ...
Breaking Medicine Technology:More than $55 billion in fines and settlements added by SCCE to its 2015 Corporate Scandal Calendar 2Closed Drug Transfer Systems to 2020 2Closed Drug Transfer Systems to 2020 3Sysmex America, Inc. Renews LABSCO Distributorship 2Sysmex America, Inc. Renews LABSCO Distributorship 3
Revised Drug calibrator that replaces existing Drug calibrator - this product contains Lithium in addition to Digoxin, Phenobarbital, OPhenytoin, & Theophulline....
... goal is to provide state-of-the-art rapid diagnostic ... Each year millions of people around the ... detection or undetected disease and illness. Diseases ... developing, manufacturing and marketing our tests to ...
Agglutination test on slide for qualitative and quantitative determination of Syphilis in serum or plasma....
... as a quality assurance reagent ... to Toxoplasma gondii (TOXO IgG), ... (rubella IgG), IgG antibody to ... antibody to herpes simplex virus ...
Medicine Products: